Argent BioPharma (MXC) Stock Price, News & Analysis

Company Overview

MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. In addition, the company provides Irnican that is in preclinical phase for the tetrahydrocannabinol, as well as offers ArtemiC and non-pharma products. Further, it offers consulting services, including clinical research services. MGC Pharmaceuticals Limited was founded in 2014 and is based in Subiaco, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2.16 million shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: 3.70%
• Price Target: N/A
• Consensus Rating: N/A

MXC Stock Analysis - Frequently Asked Questions

How were Argent BioPharma's earnings last quarter?

Argent BioPharma Limited (ASX:MXC) released its quarterly earnings results on Thursday, February, 28th. The company reported $0.00 earnings per share for the quarter.

What other stocks do shareholders of Argent BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Argent BioPharma investors own include NVIDIA (NVDA), Walt Disney (DIS), Grayscale Bitcoin Trust (GBTC), Tesla (TSLA), AbbVie (ABBV), Advanced Micro Devices (AMD) and AstraZeneca (AZN).

Company Calendar

• Last Earnings: 2/28/2019
• Today: 5/04/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: ASX:MXC
• CIK: N/A
• Web: www.mgcpharma.com.au
• Phone: 61 8 6382 3390
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($3.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-17,020,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -307.40%
• Return on Assets: -58.96%

Debt

• Debt-to-Equity Ratio: 1,436.12
• Current Ratio: 0.75
• Quick Ratio: 0.50

Sales & Book Value

• Annual Sales: $1.32 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 25.00
• Book Value: A$0.04 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 43,850,000
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.03